ESTRO 2024 - Abstract Book

S1758

Clinical - Lung

ESTRO 2024

1.9 L (range, 1.61 - 2.11). Median overall survival (OS) was 41.1 months (95% CI, 38.9 - not reached). OS rates at 2-, 3-, and 5- years were 79%, 71%, and 36%, respectively. Median cancer-specific survival (CSS) was not reached (95% CI, 53.5 - not reached). CSS rates at 2-, 3-, and 5- years were 96%, 96%, and 68%, respectively. Median disease-free survival (DFS) was not reached (95% CI, not reached - not reached). DFS rates at 2-, 3-, and 5- years were 82%, 82%, and 74%, respectively. Median local control (LC) was also not reached (95% CI, not reached - not reached). LC rates at 2-, 3-, and 5- years were 88%, 83%, and 83%, respectively. (see Figure1)